Evotec ended 2016 with the landmark deal with Celgene for Evotec’s induced pluripotent stem cell (iPSC) platform, bringing in a $45m upfront payment. Other recent highlights were Novo A/S’ €90.3m investment in the company and the acquisition of Cyprotex, an ADME-Tox and DMPK specialist that will enhance Evotec’s core service offering and also add new clients. Evotec’s Q316 results were solid, with better-than-expected margins being the main surprise for us, which
07 Mar 2017
Upgraded on healthy cash flows post acquisition
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Upgraded on healthy cash flows post acquisition
Evotec ended 2016 with the landmark deal with Celgene for Evotec’s induced pluripotent stem cell (iPSC) platform, bringing in a $45m upfront payment. Other recent highlights were Novo A/S’ €90.3m investment in the company and the acquisition of Cyprotex, an ADME-Tox and DMPK specialist that will enhance Evotec’s core service offering and also add new clients. Evotec’s Q316 results were solid, with better-than-expected margins being the main surprise for us, which